Menu
Search
|

Menu

Close
X

Fulgent Genetics Inc FLGT.OQ (NASDAQ Stock Exchange Global Market)

5.00 USD
-- (--)
As of Jul 20
chart
Previous Close 5.00
Open --
Volume --
3m Avg Volume 2,577
Today’s High --
Today’s Low --
52 Week High 6.93
52 Week Low 2.73
Shares Outstanding (mil) 17.74
Market Capitalization (mil) 84.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
19
FY16
18
FY15
4
EPS (USD)
FY18
-0.107
FY17
-0.140
FY16
-0.430
FY15
0.067
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
4.08
5.73
Price to Book (MRQ)
vs sector
1.52
5.47
Price to Cash Flow (TTM)
vs sector
53.48
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
0.05
14.61
Return on Equity (TTM)
vs sector
-1.53
16.34

EXECUTIVE LEADERSHIP

Ming Hsieh
Chairman of the Board, President, Chief Executive Officer, Since
Salary: --
Bonus: --
Paul Kim
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Hanlin Gao
Lab Director and Chief Scientific Officer, Since
Salary: --
Bonus: --
John Bolger
Director, Since
Salary: --
Bonus: --
James Mulay
Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

4978 Santa Anita Ave Ste 205
TEMPLE CITY   CA   91780-3600

Phone: +1626.3500537
Site:

Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

SPONSORED STORIES